Physician profile
Jack O Sipperley
NPI 1235130402
$12,788.84
in general payments reported to CMS, 2019-2025
15 companies · $132 in 2025
The $132 reported for 2025 was less than what a typical Retina Specialist provider received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $424 · 2021: $5,426 · 2022: $6,325 · 2023: $482 · 2025: $132.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $614.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $613.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Carl Zeiss Meditec USA, INC. | $8,808.20 | 2021-2022 | |
| Alimera Sciences, INC. | $2,028.82 | 2021-2022 | |
| Genentech USA, INC. | $532.31 | 2021-2025 | Vabysmo, Susvimo |
| Regeneron Pharmaceuticals, INC. | $350.82 | 2019-2023 | Eylea |
| Novartis Pharmaceuticals Corporation | $248.24 | 2019-2021 | |
| Biogen, INC. | $149.30 | 2022-2023 | |
| Regeneron Healthcare Solutions, INC. | $149.02 | 2019-2025 | Eylea Hd, Eylea |
| Hoffmann-La Roche Limited | $125.00 | 2021 | |
| Alcon Vision LLC | $107.83 | 2019-2022 | |
| Apellis Pharmaceuticals, INC. | $100.30 | 2023 | Syfovre |
| Bausch & Lomb Americas INC. | $76.25 | 2022-2023 | Xipere |
| Astellas Pharma US INC | $42.41 | 2025 | Izervay |
| Mallinckrodt Enterprises LLC | $37.09 | 2019 | |
| Genentech, INC. | $18.12 | 2019 | |
| Allergan, INC. | $15.13 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jack Sipperley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.